Sabra Health Care REIT: This 5.85% Healthcare REIT Is Undervalued

Philip Wang 1.23K Followers Follow Summary Sabra Health Care REIT is rated 'Buy' with a $24.50/share price target, reflecting undervaluation and strong fundamentals. SBRA reported robust Q2 results: 24.7% revenue growth, 13.7% same-store managed senior housing NOI growth, and reaffirmed 2026 AFFO guidance. Recent acquisitions totaling $599 million at attractive yields, a healthy balance sheet, and ample liquidity support ongoing external growth. Dividend yield stands at 5.85% with a sustainable 75% payout ratio, though increases are unlikely amid the current acquisition spree. erdikocak/iStock via Getty Images Introduction Sabra Health Care REIT ( SBRA ) is a healthcare REIT. Unlike some of the healthcare REITs that I have written about recently, such as Strawberry Fields REIT ( STRW ) and Diversified This article was written by Philip Wang 1.23K Followers Follow Dividend-focused investor specializing in REITs. I write fundamental deep dives on REITs, emphasizing sustainable dividends, balance sheet strength, and catalysts. Follow me for cycle-aware, income-oriented REIT ideas with clear Buy/Hold/Sell calls. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SBRA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.